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Abstract
MicroRNA are small noncoding transcripts involved in many cellular mechanisms, including tumorigenesis. miR-210,
in particular, is induced by hypoxia and correlates with adverse outcomes in certain cancers. Because pancreatic
adenocarcinomas exhibit extremely hypoxic signatures, we hypothesized that miR-210 may serve as a diagnostic
marker for screening or surveillance for pancreatic cancer. Plasma samples were obtained from newly diagnosed
pancreatic cancer patients and age-matched noncancer controls. miRNA was extracted directly from plasma and
reverse-transcribed to complementary DNA. A known quantity of synthetic Caenorhabditis elegans miR-54 (cel-
miR-54) was added for normalization. miR-210 and cel-miR-54 were then measured using quantitative reverse tran-
scription polymerase chain reaction. An initial cohort of 11 pancreatic cancer patients and 14 age-matched controls
was used as the test set and a second cohort of 11 pancreatic cancer patients and 11 controls was used as the
validating set in this study. miR-210 was reliably detected and quantified, with a statistically significant four-fold in-
crease in expression in pancreatic cancer patients compared with normal controls (P < .00004) in the test set. This
difference was confirmed in the validation group (P < .018). In summary, circulating miR-210 levels are elevated in
pancreatic cancer patients and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.
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Introduction
Pancreatic cancer remains one of the most lethal malignancies, with
most cases diagnosed after metastatic spread. Median survival in pa-
tients with locally advanced/metastatic disease is less than 12 months,
with overall 5-year survival less than 5% despite aggressive multimod-
ality treatment [1]. Tumor markers may facilitate earlier diagnosis and
have the potential for use in monitoring response to cancer therapies,
but there is no current biomarker that reliably serves this purpose.
There is, therefore, a tremendous need to identify novel noninvasive
biomarkers for early tumor detection.
MicroRNA (miRNA), a class of naturally occurring, noncoding
small RNA, regulate the expression of most genes. On a molecular
level, miRNA destabilize messenger RNA by repressing translation
and shortening the polyA tail. On a cellular level, miRNA play criti-
cal roles in differentiation, proliferation, apoptosis, and metabolism
and have ultimately been linked to cancer development [2]. Their as-
sociation with tumorigenesis has given rise to their potential for clinical
diagnosis and as therapeutic targets.
Hypoxia, or low oxygen, is an essential feature of the tumor micro-
environment, particularly in pancreatic cancer [3]. Cancers with in-
creased hypoxia exhibit poorer prognosis and greater resistance to
chemotherapy and radiation. Hypoxia has also been demonstrated to
induce differential miRNA expression [4–7]. Several investigators have
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reported that miR-210, in particular, is increased in response to hypoxia
[5,6,8,9] andmay in fact be the principalmiRNA expressed in a number
of different cancer types through a hypoxia-responsive element [4].
Interestingly, miR-210 induction is regulated by hypoxia-inducible
factor 1α (HIF-1α), and it serves as an important regulator for inhibiting
DNA repair pathways and promoting genomic instability [10]. Further-
more, miR-210 facilitates the mRNA degradation of normoxic genes,
providing another mechanism of HIF-regulated gene expression [4].
In the present study, we assessed the potential of circulating miR-210
to function as a diagnostic marker for pancreatic cancer. On the basis of
previous work by Mitchell et al. [11] and Chen et al. [12], we have
developed a plasma-based assay that reliably quantifies miR-210 from
archived patient plasma samples. Here we report that plasma miR-210
expression from patients with newly diagnosed locally advanced pan-
creatic adenocarcinomas was significantly elevated in comparison to
age-matched controls, using a test and a validating set.
Patients and Methods
Cohorts
Plasma samples for pancreatic cancer patients and controls in co-
hort 1 were collected and archived between June 2006 and January
2008, whereas plasma samples for cohort 2 were collected and archived
between March 2005 and October 2006. All samples were collected
before any treatment, and miR-210 levels were analyzed retrospectively
from these groups. All patients were identically staged with pancreatic
protocol computed tomographic scans and evaluated at the Stanford
gastrointestinal multidisciplinary tumor board. All patients had locally
advanced, unresectable stage T4 disease. Recurrent malignancies were
excluded from the study. The protocol described was first tested on
a cohort of 11 pancreatic cancer patients and 14 age-matched healthy
controls (cohort 1; Table 1). A second validation set of 11 pancre-
atic cancer patients and 11 age-matched healthy controls (cohort 2;
Table 2) was used to confirm our initial results and to achieve greater
statistical power. There was no statistically significant difference in
plasma miR-210 levels between the two control groups (2-tailed t-test,
P = .22).
Plasma Extraction
Five to ten milliliters of whole blood was obtained from each patient.
Plasma was extracted by centrifuging whole blood at 3000 rpm for
10 minutes at room temperature and then frozen as separate aliquots
at −80°C for storage. One hundred microliters of thawed plasma was
boiled for 10 minutes at 100°C and then centrifuged at 13,000g for
10 minutes at 4°C. Approximately 1.1 μl of supernatant was collected.
Complementary DNA Production
To normalize by volume, synthetic Caenorhabditis elegans miR-54
(cel-miR-54) (Integrated DNA Technologies, Coralville, IA) served
as a control. cel-miR-54 has previously been shown not to affect
human miRNA detection [11]. Complementary DNA was generated
by mixing the extracted RNA (1.1 μl) with 5× miR-210 primer
(1.0 μl), 5× cel miR-54 primer (0.9 μl), 0.25 nM cel miR-54 oligo
(0.1 μl), 5× First Strand buffer (1.0 μl), dithiothreitol (0.5 μl),
25mMdNTP (0.2 μl), RNAse Out Inhibitor (0.1 μl), and reverse tran-
scriptase (0.1 μl). This mixture was assayed on a standard polymerase
chain reaction (PCR) thermal cycler at 16°C for 30 minutes, at 42°C
for 30 minutes, at 85°C for 5 minutes, and then at 4°C afterward.
Quantitative Reverse Transcription–PCR
Quantitative reverse transcription–PCR (qRT-PCR) was performed
using an ABI 7900 Thermal Cycler, with miR-54 and miR-210 quan-
tified using TaqMan MicroRNA Assays (Applied Biosystems, Foster
City, CA). Twenty-five microliters of dH2O was mixed with 5 μl of
complementary DNA. Four microliters of this dilution was mixed with
2× Master Mix (5 μl), 20× PCR Primer (0.5 μl), and dH2O (0.5 μl)
before being pipetted onto a 394-well plate. qRT-PCR was then per-
formed at 50°C for 2 minutes, at 95°C for 10 minutes, at 95°C for
15 seconds, and at 60°C for 60 seconds, with the last two steps re-
peated for a total of 40 cycles. Each reaction was performed in triplicate.
Table 1. Cohort 1.
Cohort 1 Patient ID Age (years) Location CA 19-9 (U/ml) miR-210 Expression (Mean ± SD)
Pancreas CA P1 85 Head 24 1.41 ± 0.16
P2 60 Head 243 2.37 ± 0.70
P3 60 Head 235 4.46 ± 2.04
P4 68 Head 4514 1.82 ± 0.50
P5 65 Head 1270 0.51 ± 0.12
P6 57 Head <1 1.57 ± 0.13
P7 60 Body 66 3.53 ± 0.08
P8 63 Head 1 1.43 ± 0.14
P9 51 Body 168 3.31 ± 0.69
P10 79 Body 327 1.20 ± 0.31
P11 46 Head 40 1.77 ± 0.18
Controls C1 64 0.44 ± 0.49
C2 59 0.64 ± 0.48
C3 58 0.48 ± 0.51
C4 61 0.55 ± 0.68
C5 49 0.24 ± 0.48
C6 58 0.45 ± 0.26
C7 66 0.53 ± 0.19
C8 62 0.54 ± 0.12
C9 55 0.17 ± 0.14
C10 58 0.46 ± 0.06
C11 51 0.42 ± 0.03
C12 61 0.68 ± 0.10
C13 62 0.81 ± 0.15
C14 60 0.82 ± 0.04
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Standard curves were generated for miR-54 and miR-210 out to
1:1024 dilutions. C t values thresholds were set at 0.1.
MicroRNA Stability in Plasma
Samples were subjected to a number of harsh conditions, and
microRNA levels were subsequently quantified. Different plasma ali-
quots of the same sample were used for each condition. Conditions
encompassed doubling the boiling time to 20 minutes, incubating at
room temperature (at 4-, 12-, and 24-hour intervals), and undergoing
multiple freeze/thaw cycles between −80°C storage and room tempera-
ture. qRT-PCR was then performed, and raw C t values of miR-54 and
miR-210 were compared with the standard protocol.
Carbohydrate Antigen 19-9 Assay
Two milliliters of blood was drawn from each pancreatic cancer
patient before treatment, and the serum component was extracted.
Carbohydrate antigen 19-9 (CA 19-9) was quantified by the Stanford
Hospital Clinical Laboratory using the ADVIA Centaur 19-9 assay, a
two-step sandwich immunoassay using chemiluminescence and 1116-
NS-19-9 as a monoclonal antibody (Siemens Diagnostic Healthcare,
Deerfield, IL).
Statistics
miR-210 levels were expressed as the mean of the triplicate C t values
on each qRT-PCR run. Normalized values were generated using the
ΔΔC t method. Paired Student’s t test was used to evaluate the differ-
ence between pancreatic cancer patients and normal controls as well
between the two control groups. A difference was regarded as statisti-
cally significant for a 2-tailed P < .05. Simple regression analysis was
used to correlate miR-210 and CA 19-9 levels.
Table 2. Cohort 2.
Cohort 2 Patient ID Age (years) Location CA 19-9 (U/ml) miR-210 Expression (Mean ± SD)
Pancreas CA P12 52 Head 8320 1.27 ± 0.04
P13 77 Head 88 1.80 ± 0.11
P14 43 Head 2950 0.69 ± 0.07
P15 58 Body <1 1.67 ± 0.00
P16 54 Body 7.1 2.69 ± 0.13
P17 60 Head 568 2.23 ± 0.11
P18 59 Body 1329 0.57 ± 0.02
P19 56 Head 16.7 1.58 ± 0.06
P20 69 Head 26 0.77 ± 0.00
P21 62 Head <3 0.68 ± 0.05
P22 64 Head 11.6 1.65 ± 0.04
Controls C15 40 1.10 ± 0.02
C16 65 0.76 ± 0.10
C17 55 0.35 ± 0.00
C18 51 0.95 ± 0.02
C19 60 0.55 ± 0.06
C20 44 0.97 ± 0.07
C21 58 1.11 ± 0.04
C22 64 1.02 ± 0.02
C23 46 0.62 ± 0.00
C24 44 1.06 ± 0.06
C25 45 0.76 ± 0.09
Figure 1. Plasma levels of miR-54 and miR-210 were found to be stable after being subjected to various harsh conditions. Boiling tem-
peratures were at 100°C. Freeze-thaw cycles were at −80°C and room temperature, respectively, reflecting protocol and storage settings.
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Results
Detection and Quantification of miR-210 in Plasma
Although plasma is known to contain ribonuclease, we found that
miRNA species were present and resistant to RNAse digestion. More-
over, the stability of plasma miRNA persisted even after subjecting
samples to different conditions, including boiling, maintaining at room
temperature for several hours, and multiple freeze-thaw cycles (Fig-
ure 1). The qRT-PCR analysis of miR-54 and miR-210 under these
conditions yielded no significant differences compared with untreated
plasma, indicating this protocol to be robust and reproducible.
miR-210 Overexpression in Pancreatic Cancer
To assess levels of miR-210, plasma samples from human pancreatic
cancer patients and age-matched controls were collected (cohorts 1 and
2). Pancreatic cancer was chosen as a model system due to the severe
hypoxia present in these tumors [3]. In cohort 1, circulating miR-210,
normalized to miR-54, was found to be significantly elevated compared
with normal controls, using the ΔΔC t method (4.0× overexpression,
P < .00004; Figure 2 and Table 1). A second set of pancreatic cancer
patients and healthy controls (cohort 2) was independently analyzed
to validate the first set’s findings. Once again, significantly higher cir-
culating miR-210 level was noted for cancer patients (1.7× overexpres-
sion, P < .018; Figure 3 and Table 2). The qRT-PCR results support
the concept that miR-210 may serve as a reliable blood-based bio-
marker, using a minimum amount of sample (100 μl). The differences
between miR-210 levels in the two control groups were not signifi-
cantly different (P = .22).
No correlation was identified between pretreatment CA 19-9 (Ta-
bles 1 and 2) and miR-210 levels in either cohort 1 or cohort 2. The
overall correlation coefficient between miR-210 and CA 19-9 levels
for all patients was 0.21 (P = .33).
Figure 2. Cohort 1 pancreatic cancer patients exhibited significantly higher circulating miR-210 levels compared with healthy, age-matched
controls in plasma (4.0× overexpression, P < .00004). Relative expression was calculated by 2−(C t value − average C t value).
Figure 3. Cohort 2 pancreatic cancer patients demonstrated a similar elevation of miR-210 levels compared with age-matched controls
(1.7× overexpression, P < .018). Relative expression was calculated by 2−(C t value − average C t value).
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Discussion
Altered miRNA expression has been reported in various cancers, and the
dysregulation of tissue miRNA exhibits great potential for identifying
malignancy. Hypoxic tumors in particular exhibit poor prognosis and
resistance to conventional therapy, and miRNA likely mediate the di-
verse epigenetic mechanisms resulting in this phenotype [2]. miR-210,
in particular, has garnered significant attention in relation to hypoxia
and cancer: it is an important mediator of the endothelial cell response
to low oxygen tension, and it has emerged as a near-universal responder
to hypoxia [5]. Clinically, recent data by Camps et al. [9] show that
miR-210 in human breast cancer is not only a marker of tumor hypoxia
in vivo but also an indicator of adverse prognosis. We previously found
that miR-210 is directly regulated by HIF-1α in a variety of tumor types
through a hypoxia-responsive element [4]. Functional studies further
suggest that miR-210 suppresses normoxic genes that are no longer nec-
essary for adaptation and survival in a hypoxic environment [4].miR-210
has also been found to promote cell cycle progression by activating
c-MYC through inhibition of a c-MYC antagonist [13].
Tissue-based diagnosis remains invasive and time-intensive. Serum
and plasma have been extensively researched, yet such minimally in-
vasive tests are still limited for use in tumor detection. Recent studies
in prostate cancer by Mitchell et al. [11] and Chen et al. [12] have
established that miRNA is stable and quantifiable in plasma. These re-
markable properties remain unexplained, although hypotheses include
modifications to their structure and associations with protective mole-
cules such as exosomes [11]. In the present study on pancreatic cancer,
we have developed a robust protocol that uses minimal plasma sample
and is well suited for high-throughput analysis. To normalize sample-
to-sample variation in RNA isolation, synthetic C. elegans miR-54
oligonucleotide was spiked into each sample and quantified. cel-miR-54
was chosen as a control based on findings that it does not cross-hybridize
with probes for known human miRNA [11].
Using this protocol, we found that miR-210 level was significantly
elevated in human pancreatic cancer plasma samples in two indepen-
dent patient cohorts, 4.0-fold and 1.7-fold, respectively. We chose
to evaluate miRNA in pancreatic cancer because the hypoxic tumor
microenvironment plays a crucial role in the progression of these ma-
lignancies [3,14]. While this article was under review, Wang et al. [15]
published similar findings regarding microRNA and pancreatic cancer,
demonstrating that combined analyses of four different miRNA (in-
cluding miR-210) in plasma could distinguish pancreatic cancer pa-
tients from healthy individuals. Notably, their extraction of miRNA
was different from our methodology, requiring overnight incubation
and column purification. Our conclusions corroborate the findings
of Wang et al., further establishing miR-210 as a pancreatic cancer
biomarker and substantiating the concept of plasma miRNA stability
through a novel assay technique.
Our study noted no direct correlation between circulating miR-210
levels and CA 19-9, which was not unexpected because the two factors
are presumably regulated by different mechanisms. Because sample size
was modest and CA 19-9 was not measured in the control population,
it was not feasible to determine the statistical contribution of miR-210
in addition to CA 19-9 for the detection of malignancy in our cohorts.
Drawbacks from our study include its small sample size and its
retrospective nature. Nonetheless, the presence of elevated miR-210
in the plasma of pancreatic cancer patients suggests that this may be
an important feature of this disease, which may further advance our
understanding of the underlying pathogenesis of pancreatic cancer.
Moreover, given the exquisite sensitivity of qRT-PCR, miR-210 levels
could also facilitate earlier diagnosis and treatment of this malignancy.
The abundance and stability of miRNA in plasma further indicate
that these blood-based biomarkers have great potential for use to pre-
dict the clinical behavior of individual cancers and to monitor thera-
peutic responses.
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